Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
We work with you to create a personalized semaglutide treatment plan that fits your life, your goals, and yeseven your social habits
A batch analysed on 27 July 2026 returned 99.85% purity by area at 220 nm
These drugs can help you reach your A1C goal, which can prevent diabetes complications like heart and blood vessel disease, nerve or vision damage, and kidney failure
Regulatory History Empowers enforcement record spans nearly a decade across both its 503A and 503B operations: 2017 FDA Warning Letter issued after a 2015 inspection found that Empower produced drug products without valid prescriptions for individually identified patients, and that sterile drug products were prepared under insanitary conditions that put patients at risk 2021 FDA Warning Letter issued to the 503B outsourcing facility after a 2020 inspection found that drug products failed to meet the conditions of Section 503B of the FDCA 2024 FDA Form 483 documented fill weight discrepancies in semaglutide vials, inadequate quality control sampling procedures, and deficiencies in aseptic processing areas April 2025 FDA Warning Letter cited drug products intended or expected to be sterile that were prepared, packed, or held under insanitary conditions
Primary study: Wilding and colleagues, 2022, Diabetes, Obesity and Metabolism
doi:10.1016/s0167-0115(03)00120-4 5
